Emcure Pharmaceuticals on Thursday announced a royalty-free voluntary licensing agreement with Gilead Sciences Ireland UC, a subsidiary of the California-based Gilead Sciences, to manufacture and supply generic versions of lenacapavir.
Lenacapavir is an important medication for HIV prevention and treatment.
The agreement aims to bolster access to lenacapavir in 120 countries, with a particular focus on resource-limited nations that experience high rates of HIV infection.
By providing high-quality, low-cost versions of the drug, Emcure hopes to make a meaningful impact in regions where such treatments are urgently needed, the company said in a press release.
Satish Mehta, Managing Director and CEO of Emcure Pharmaceuticals, expressed his thoughts on the collaboration, stating, "We are proud to partner with Gilead in this global initiative to expand access to critical HIV medicines."
Mehta highlighted Emcure's established presence in the HIV antiviral market in India and its experience supplying HIV medications to over 100 low- and middle-income countries (LMICs).
"Emcure is uniquely positioned to drive impactful change in the global fight against HIV," Mehta added. "By bringing lenacapavir to the regions that need it most, we are taking a step forward in improving health outcomes worldwide."
Emcure's involvement is seen as a critical step toward addressing the challenges faced by those living with HIV in economically disadvantaged regions, the company said.
About Lenacapavir
Lenacapavir, a promising antiviral treatment, has garnered approval in multiple countries for managing adults with multi-drug resistant HIV, typically used in combination with other antiretrovirals.
However, its application for HIV prevention remains investigational, and the "safety and efficacy of lenacapavir for this use have not been established," according to Emcure pharmaceuticals.
Ongoing research is focusing on lenacapavir as a long-acting option in both early and late-stage clinical studies within Gilead's HIV prevention and treatment research program.
The aim is to develop lenacapavir as a foundation for future HIV therapies, providing both oral and injectable options that offer different dosing frequencies. This approach seeks to meet the diverse needs and preferences of individuals and communities affected by HIV.
Lenacapavir is an important medication for HIV prevention and treatment.
The agreement aims to bolster access to lenacapavir in 120 countries, with a particular focus on resource-limited nations that experience high rates of HIV infection.
By providing high-quality, low-cost versions of the drug, Emcure hopes to make a meaningful impact in regions where such treatments are urgently needed, the company said in a press release.
Satish Mehta, Managing Director and CEO of Emcure Pharmaceuticals, expressed his thoughts on the collaboration, stating, "We are proud to partner with Gilead in this global initiative to expand access to critical HIV medicines."
Mehta highlighted Emcure's established presence in the HIV antiviral market in India and its experience supplying HIV medications to over 100 low- and middle-income countries (LMICs).
"Emcure is uniquely positioned to drive impactful change in the global fight against HIV," Mehta added. "By bringing lenacapavir to the regions that need it most, we are taking a step forward in improving health outcomes worldwide."
Emcure's involvement is seen as a critical step toward addressing the challenges faced by those living with HIV in economically disadvantaged regions, the company said.
About Lenacapavir
Lenacapavir, a promising antiviral treatment, has garnered approval in multiple countries for managing adults with multi-drug resistant HIV, typically used in combination with other antiretrovirals.
However, its application for HIV prevention remains investigational, and the "safety and efficacy of lenacapavir for this use have not been established," according to Emcure pharmaceuticals.
Ongoing research is focusing on lenacapavir as a long-acting option in both early and late-stage clinical studies within Gilead's HIV prevention and treatment research program.
The aim is to develop lenacapavir as a foundation for future HIV therapies, providing both oral and injectable options that offer different dosing frequencies. This approach seeks to meet the diverse needs and preferences of individuals and communities affected by HIV.
You may also like
This Morning's Cat Deeley and Ben Shephard issued major blow as Holly is set to 'return'
I wanted to sign for Tottenham but Arsenal director stopped me
Mohamed Salah reveals ex-Arsenal star showed him he could be Liverpool record-breaker
Keir Starmer's Diplomacy: Paving the Way for Enhanced UK-EU Relations
